Table 8.
Results of the base-case (first-line therapies) and scenario (second-line therapies) probabilistic analyses
| Treatment | Total cost (CAD) | LY | QALY | Incremental cost of ofatumumab vs comparator (CAD) | Incremental QALY of ofatumumab vs comparator | ICER ($ per QALY) vs ofatumumab |
|---|---|---|---|---|---|---|
| Base case analysis (first-line therapies) | ||||||
| Ofatumumab | 743,015 (739,331–746,700) | 28.406 (28.392–28.420) | 9.277 (9.215–9.339) | |||
| Ocrelizumab | 784,832 (780,987–788,678) | 28.383 (28.369–28.398) | 9.145 (9.077–9.212) | − 41,817 (− 43,364 to − 40,270) | 0.132 (0.091–0.173) | Ofatumumab dominant |
| Teriflunomide | 761,998 (757,775–766,221) | 28.170 (28.155–28.184) | 7.950 (7.894–8.006) | − 18,983 (− 20,410 to − 17,555) | 1.327 (1.293–1.361) | Ofatumumab dominant |
| Dimethyl fumarate | 771,029 (766,988–775,070) | 28.238 (28.224–28.253) | 8.341 (8.284–8.397) | − 28,014 (− 29,340 to − 26,688) | 0.936 (0.903–0.969) | Ofatumumab dominant |
| Glatiramer acetate | 713,474 (709,330–717,619) | 28.190 (28.175–28.205) | 8.056 (7.997–8.115) | 29,541 (28,116 to 30,966) | 1.221 (1.187–1.256) | $24,189 |
| Avonex | 770,188 ($766,116–774,259) | 28.216 (28.202–28.231) | 8.118 (8.062–8.175) | − 27,173 (− 28,451 to − 25,894) | 1.158 (1.127–1.189) | Ofatumumab dominant |
| Rebif 22 | 756,048 (751,998–760,098) | 28.202 (28.187–28.217) | 8.085 (8.028–8.142) | − 13,033 (− 14,393 to − 11,672) | 1.192 (1.158–1.226) | Ofatumumab dominant |
| Rebif 44 | 781,810 (777,612–786,008) | 28.178 (28.163–28.193) | 7.994 (7.936–8.052) | − 38,795 (− 40,362 to − 37,227) | 1.283 (1.244–1.321) | Ofatumumab dominant |
| Betaseron | 759,927 (755,753–764,100) | 28.189 (28.175–28.204) | 8.041 (7.982–8.099) | − 16,911 (− 18,335 to − 15,487) | 1.236 (1.202–1.270) | Ofatumumab dominant |
| Extavia | 755,037 (750,843–759,232) | 28.189 (28.174–28.204) | 8.032 (7.977–8.088) | − 12,022 (− 13,518 to − 10,527) | 1.245 (1.209–1.280) | Ofatumumab dominant |
| BSC | 689,506 (685,203–693,810) | 28.073 (28.059–28.088) | 7.367 (7.317–7.416) | 53,509 (52,339 to 54,679) | 1.910 (1.883–1.937) | $28,014 |
| Scenario analysis (second-line therapies) | ||||||
| Cladribine | 715,734 (711,796–719,671) | 28.311 (28.297–28.325) | 8.742 (8.683–8.800) | 27,282 (25,948 to 28,615) | 0.535 (0.502–0.568) | $50,969 |
| Natalizumab | 869,833 (865,872–873,793) | 28.382 (28.368–28.396) | 9.138 (9.078–9.198) | − 126,818 (− 128,603 to − 125,032) | 0.139 (0.103–0.174) | Ofatumumab dominant |
| Fingolimod | 772,790 (768,805–776,776) | 28.251 (28.236–28.265) | 8.422 (8.364–8.479) | − 29,775 (− 31,093 to − 28,457) | 0.855 (0.822–0.888) | Ofatumumab dominant |
Data are presented as mean (95% confidence interval).
BSC best supportive care, CAD Canadian dollars, ICER incremental cost-effectiveness ratio, LY life-years, QALY quality-adjusted life-year